Seeking Alpha

Piper Jaffray raises its price target on shares of Clovis Oncology (CLVS) just slightly from $36...

Piper Jaffray raises its price target on shares of Clovis Oncology (CLVS) just slightly from $36 to $100 (rating understandably lifted to Overweight from Neutral). Piper cites the CO-1686 data delivered at ASCO (previous). Shares +6.7% premarket and +93% since last week. (Also: SA contributor Brian Wilson's analysis of CO-1686)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs